Moreover, more recently, supplementation of mice with L.RGG has been shown to induce CD8+ T cells through TLR2-mediated activation of DCs [51]; in melanoma and colorectal cancer murine models, L.RGG administration triggered type I interferon production in DCs enhancing the cross-priming of antitumor CD8+ T cells [52]. This evidence concerns the gene CD8A and melanoma.